These pharma companies got an American shock! Impact may be visible on shares

Due to manufacturing defects in the American market, Indian pharma companies Aurobindo Pharma, Glenmark and Zydus have withdrawn their products from the market. According to the latest enforcement report of the US Food and Drug Administration (USFDA), this step has been taken due to manufacturing irregularities in these medicines.

Aurobindo Pharma’s step p>

Aurobindo Pharma USA Inc, a subsidiary of Hyderabad-based Aurobindo Pharma, has recalled more than one lakh bottles of Cinacalcet tablets. These pills are used in the treatment of hyperparathyroidism. USFDA said that the amount of N-nitroso cinacalcet impurity found in these tablets was more than the limit recommended by FDA. The company started the process of recalling these products under Class-2 category on November 7 this year.

Glenmark’s withdrawal

Glenmark Pharma’s The American subsidiary has recalled about 90,000 bottles of diltiazem hydrochloride capsules. These medicines are used to treat high blood pressure and heart related problems. This recall is also due to manufacturing defects. Has been called back. This medicine is used to treat problems of the stomach and esophagus, such as gastroesophageal reflux disease (GERD). The company started the process of recalling the affected products from the market on November 14.

Impact on the stock market

These incidents will be known in the trading session on Friday. The effect was seen on the shares of the companies. Shares of Aurobindo Pharma fell 0.59% or 7.20 points to close at Rs 1207.95. Glenmark Pharma shares closed at Rs 1517.20 with a decline of 1.13% or 17.30 points. Shares of Zydus Lifescience closed at Rs 978.35 with a rise of 0.28% or 2.70 points.

What is the future challenge?

Indian pharma companies The American market is very important for us, but meeting the manufacturing standards remains challenging. Recall of products affects the image and profits of companies. Due to the strictness of USFDA, companies will have to further improve their production process to comply with the quality standards.

Disclaimer: (The information provided here is being given for information only. It is important to mention here Investing in the market is subject to market risks. Before investing money, ABPLive.com never advises anyone to invest. >